Peripheral Blood Oxygen Saturation: A Non-invasive Prognostic Marker in Cancer Patients Treated with Radiation Therapy- A Pilot Study

Savitha David1,* and V Lokesh1

1Department of Radiation Oncology, KIDWAI memorial institute of Oncology, Bengaluru, India

Abstract:

Aims:
1. To evaluate the prognostic value of SpO2 in cancer patients
2. To correlate between daily SpO2 values and tumor response to radiation.

Background:
Tumor hypoxia is an important prognostic factor in Oncology. It plays an important role in tumorigenesis, radiation resistance and tumor progression. Many invasive and in-vitro methods are available to assess the hypo-oxygenated status of tumors.

Objective:
We evaluated if SpO2 values measured from pulse oximetry could be used as an adjunct prognostic and predictive factor in oncology patients.

Methods:
Ten consecutive patients with locally advanced, non-metastatic disease were evaluated. Daily SpO2 measurements throughout the treatment and weekly haemoglobin values were noted. All patients received radical intent radiation therapy. Patients were categorised into two groups: poor SpO2 (<97mmHg) and better SpO2 (≥98mmHg).

Results:
Tumour response was higher in patients with better SpO2 (≥98mmHg). Patients with poor SpO2 (<97mmHg) presented with bulkier disease at diagnosis.

Conclusion:
Role of SpO2 as a prognostic and predictive factor should be explored further with in vitro and pH studies.

Keywords: Pulse oximetry, Prognostic, Cancer, SpO2 Value, Tumorogenesis, Oncology.

1. INTRODUCTION

Prognostic and predictive factors have been the Holy Grail of Oncology. To find ideal prognostic factors, which can choose patients for a particular treatment, tailor the intervention, reduce toxicities and improve survival, has been science's pursuit. Currently, many modalities are available for diagnosis and progostication, such as imaging, scopies, tumour markers and the gold standard histopathological analysis [1]. Nevertheless, they have their own set of disadvantages, such as they are invasive, expensive and require expertise. Research has been ongoing to find prognostic markers which are direct, easy-to-interpret, cost-effective and preferably non-invasive [2].

Oxygen has been long since known to play a critical role in the response of tumour to radiation and has been proven to be a prognostic factor clinically [3]. Many of the methods used to determine the oxygen saturation of cancerous tumours include the use of invasive techniques such as probes and assays [4] in this study, we reported the use of SpO2 values from Pulse oximetry as a non-invasive prognostic factor in patients with
2. METHODOLOGY

2.1. Study Details

It is a single-institution, prospective pilot study conducted between October - November 2019. For each patient, detailed history and clinical evaluation, along with necessary haematological and radiological investigations were obtained. After counselling patients regarding disease status and study, informed consent was taken. Inclusion criteria included patients above 18 years of age and ECOG (Eastern Cooperative Oncology Group) status of 0-2 with biopsy-proven locally advanced malignancy. Exclusion criteria included patients with metastatic disease, post-operative status, prior neoadjuvant chemotherapy, co-morbidities such as uncontrolled diabetes, hypertension, chronic obstructive pulmonary disease or cardiac dysfunction. Patients with spirometry FEV1/FEV ratio of less than 70% were excluded from the study. Only patients with good respiratory effort were included in the study. Due to the possibility of mechanical airway obstruction in locally advanced bulky head and neck cancers and the confounding bias of effects of smoking and clinical sequelae of pulmonary tuberculosis (such as emphysema, atelectasis), only patients who were clinically asymptomatic and with clear lungs on chest CT scan were included in this study. Patients who underwent adjuvant surgery or chemotherapy within 6 weeks of completing concurrent chemoradiation were excluded.

2.2. Treatment Details and Study Endpoint

All underwent simulation CT scan of the respective area to be treated. The head and neck patients were immobilised with a thermoplastic mask and simulated from vertex to carina; the esophageal patients were simulated from mandible till third lumbar vertebra; the cervix uteri lesion patients were simulated from diaphragm to mid-thigh. All received intravenous iodinated contrast during the simulation.

The primary and the significant nodes were delineated as single GTV (Gross Tumor Volume) and considered as \( V_{\text{initial}} \) = Volume prior to treatment in cc. The CTV (Clinical Target Volume) and PTV (Planning Target Volume) were delineated according to guidelines. Patients were planned either by 3DCRT, IMRT or VMAT according to the physician's discretion. All patients were planned for aradical intent dose of 50.4 Gy in 28 fractions, 1.8 Gy per fraction, one fraction per day over 6 weeks; cancer cervix uteri patients received a total dose of 70 Gy in 35 fractions, 2 Gy per fraction, one fraction per day over 7 weeks, the esophageal tumours received a total dose of 50.4 Gy in 28 fractions, 1.8 Gy per fraction, one fraction per day, over 6 weeks; cancer cervix uteri patients received 45 Gy in 25 fractions, 1.8 Gy per fraction, one fraction per day, over 5 weeks followed by Brachytherapy 7 Gy x 3 fractions. Out of 10 patients, eight received concurrent weekly CDDP chemotherapy; two head and neck patients did not receive any concurrent chemotherapy in view of renal co-morbidities. All patients completed the planned therapy without any treatment breaks.

None of the patients smoked during the study period. 6 out of 10 patients had a previous history of smoking and 2 patients had sputum-negative, treated pulmonary tuberculosis with no lung sequelae. All patients had good respiratory effort throughout the treatment (Table 2).

Analysing all patients together (Table 3), for \( n=10 \) patients, the mean burden of tumour at baseline \( V_{\text{initial}} \) mean was 85.99 cc [range: 20.2 - 242 cc]. Following radiation therapy, the \( V_{\text{post- treatment}} \) had reduced to a mean of 27.37 cc [range: 0 - 92.2 cc]. Hence all patients responded to radiation and the mean reduction in tumor volume by 67.7% compared to baseline.

The patients were analysed further by grouping them into two categories. The mean SpO2 reading of each patient throughout the treatment period was tabulated and patients were categorised into poor SpO2 (less than 97%) and better SpO2 (more than or equal to 98%) groups. Student's t-test was employed to correlate the mean of the two groups to the reduction in disease (Table 4). It was found that patients with poor SpO2 had a mean residual disease of 77.1 cc (standard deviation ± 21.356) and patients with better SpO2 had lower mean residual disease of 14.938 cc (standard deviation
Peripheral Blood Oxygen Saturation

A±11.5772)(see Graph 1). In simple words, patients with <97mmHg SpO2 will have a larger residual disease at the end of treatment and hence respond poorly to radiation. Patients with mean SpO2 ≥98mmHg respond better to treatment and the tumour reduction/response is greater to radiation.(see Graph 2 and 3)

According to RECIST criteria 1.1, one patient [who belonged to the 'better SpO2' group] had complete response, i.e., no residual disease, the rest nine had a partial response (more than 30% reduction). None had progressive or stable disease.

Spearman's rho analysis showed a negative correlation between mean SpO2 and bulk of disease at presentation (-0.675, Table 5). This leads to the interpretation that patients with poorer mean SpO2 present with bulkier disease and patients with better SpO2 have lesser tumor burden at presentation (see Graph 4)

The mean haemoglobin of the patients through the treatment was 12.16 g/dl [range: 11.2- 14 g/dl]. There was no correlation between haemoglobin with either disease response or SpO2 levels (Table 6 and Graph 5).

Table 1. Patient characteristics and treatment details.

| Patient ID | Sub-site       | Gender | Age | Presenting Symptom                  | History of Smoking | Histology | Stage of Disease | Radiation Dose | Concurrent Chemotherapy | V1(cc) | V2(cc) | Mean SpO2 |
|------------|----------------|--------|-----|------------------------------------|--------------------|-----------|------------------|---------------|------------------------|-------|-------|----------|
| 1          | Hypopharynx    | Male   | 65  | Pain on swallowing (odynophagia)   | Yes                | SCC       | T4aN1            | *70/35        | No                     | 25.3  | 12.5  | 98.17    |
| 2          | Base of Tongue | Male   | 67  | Pain on swallowing (odynophagia)   | Yes                | SCC       | T4aN2b           | *70/35        | Yes                    | 62    | 14    | 98.36    |
| 3          | Cervix uteri   | Female | 57  | Bleeding per vaginum              | No                 | SCC       | IIIIB            | *50/25+ ISBT 7Gyx3# | Yes                   | 209.5 | 92.2  | 97.36    |
| 4          | Nasopharynx    | Female | 38  | Bleeding from nostrils             | No                 | Undifferentiated | T3N2       | *50/25+ 24/12 | Yes                    | 45.9  | 0     | 97.53    |
| 5          | Hypopharynx    | Male   | 44  | Pain on swallowing                | No                 | SCC       | T4aN2b           | *70/35        | Yes                    | 23.7  | 5.03  | 98.73    |
| 6          | Cervix uteri   | Female | 39  | Bleeding per vaginum              | No                 | SCC       | IIIIB            | 50/25+ ISBT 7Gy3# | Yes                   | 242   | 62    | 97.2     |
| 7          | Esophagus      | Male   | 56  | Difficulty in swallowing          | Yes                | SCC       | T4N0             | *50.4/28      | Yes                    | 125.5 | 33.01 | 99.08    |
| 8          | Supraglottis   | Male   | 77  | Hoarsness of voice                | Yes                | SCC       | T3N2c            | *70/35        | No                     | 72    | 31    | 97.88    |
| 9          | Esophagus      | Male   | 53  | Difficulty in swallowing          | Yes                | SCC       | T4N0             | *50.4/28      | Yes                    | 33.8  | 14    | 98.68    |
| 10         | Vallecula      | Male   | 65  | Pain while swallowing             | Yes                | SCC       | T3N0             | *70/35        | Yes                    | 20.2  | 10    | 98.58    |

abbreviation: SCC=squamous cell carcinoma; $V1=$volume of disease prior to treatment; $V2=$ volume of residual disease post-treatment; *2 Gy per fraction, one fraction per day, over 7 weeks; @ 1.8 Gy per fraction, one fraction per day, over 6 weeks; $\oplus$ 2 Gy per fraction, one fraction per day, over 5 weeks followed by ISBT(Interstitial Brachytherapy) 7 Gy in 3 fractions over 2 weeks;$\$ cDDP 40 mg /m2 weekly; patients 3 and 5 had past pulmonary tuberculosis, treated and tested sputum-negative before initiation of treatment.

Table 2. Patient characteristics and treatment details.

| Subsite               | SpO2<97mmHg | SpO2 % 98 |
|-----------------------|-------------|-----------|
| Number of patients    | 2           | 8         |
| Subsite               | Cervix uteri=2 |
| Nasopharynx=1         | Base of Tongue=1 |
| Valentula =1          | Hypopharynx=2 |
| Supraglottis=1        | Esophagus =1  |
| Histology             | Squamous cell carcinoma |
| Undifferentiated      | 2           | 7         |

Table 2. Patient characteristics and treatment details.
The Open Cancer Immunology Journal, 2020, Volume 8

David and Lokesh

| Parameter                  | Mean   | Range      |
|----------------------------|--------|------------|
| V initial                  | 85.99 cc | 20.2- 242 cc |
| V post-treatment           | 27.37 cc | 0- 92.2 cc |
| Percentage reduction in volume [(V1-V2)/V1] % | 67.7% | 50.7- 100% |
| SpO2 readings              | 98.16% | 95-100%    |
| Haemoglobin                | 12.16 g/dl | 11.2- 14 g/dl |

Table 4. Student's t-test analysis between V post-treatment and mean of SpO2 of the two groups.

| SpO2 group            | N  | Mean  | Standard deviation | Standard Error Mean | p value |
|-----------------------|----|-------|--------------------|---------------------|---------|
| V post-treatment      |    |       |                    |                     |         |
| <97 mmHg              | 2  | 77.100| 21.3546            | 15.1000             | <0.001  |
| (poor SpO2) % >98mmHg (better SpO2) | 8  | 14.938| 11.5772            | 4.0932              | significant |

Graph (1). Patients with poor SpO2 values have more residual disease at the end of therapy compared to patients with better SpO2 values (mean 77.1 cc vs 14.94cc).
Peripheral Blood Oxygen Saturation

**Graph (2).** Line graph illustrating the pattern of reduction of tumor between the two groups.

**Table 5.** Spearman’s rho analysis.

| $V_{\text{final}}$ with SpO2 | correlation coefficient | sig.(2 tailed) |
|-------------------------------|-------------------------|----------------|
| -0.675                        | -0.675                  | 0.032          |

**Graph (3).** Percentage reduction of disease between the two SpO2 groups. The reduction is more in patients with SpO2 % 98mmHg (70.72% vs 65.84%).

**Graph (4).** Patients with poor SpO2 present with bulkier disease compared to patients with better SpO2 who have a lesser burden of disease at presentation (mean: 225.75 cc vs 51.05cc).

**Graph (5).** Mean haemoglobin between the two groups.
Table 6. Student’s t-test analysis between mean hemoglobin and mean of SpO2 of the two groups.

| t-test | SpO2 group | N | Mean | Standard deviation | Standard Error Mean | p value |
|--------|------------|---|------|-------------------|---------------------|---------|
| -      | <97 mmHg (poor SpO2) | 2 | 11.5 | 2.12 | 1.5 | Not significant |
| -      | % 98mmHg (better SpO2) | 8 | 12.38 | 1.061 | 0.375 | Not significant |

4. DISCUSSION

Many prognostic and predictive factors are available clinically to aid in the treatment, management and counselling of oncology patients. Amongst the 6 ‘R’s of radiobiology, re-oxygenation has been explored extensively, both theoretically and clinically. Since the early 90s, studies on tumour tissue of various sites such as Head and neck and cervical cancers have demonstrated prognostic significance of intra-tumoral oxygenation and pH. This applied knowledge has led to the emergence of strategies such as the use of vasoactive agents, hyperbaric oxygen, hyperthermia, radiosensitizers and hypoxic cell modifiers [5]. The use of altered fraction regimens of hyperfractionation to increase functional oxygenation has been tried [6]. Non-invasive imaging techniques such as PET scans, 18F FMIso, 18F Faza- based on the principles of hypoxia are on the rise [7]. There is ongoing research to combine targeting hypoxia and immune check-points to augment immunological response of the host [8].

In this study, the patients’ daily SpO2 measurements during treatment were studied and correlated with disease response. The aim was to find out if SpO2 values of the patient can be used as a surrogate for the oxygenated status of the oncology patients and be used clinically as prognostic and predictive markers.

The functioning of pulse oximetry is based on the principle of spectrophotometry, where the absorption of light is measured using two wavelengths: 660nm (red) for oxygenated and 940nm (infrared) for deoxygenated blood. The ratio of absorbance at these wavelengths is calibrated against direct measurements of arterial oxygen saturation (SaO2) to establish the pulse oximeter’s measure of arterial saturation (SpO2). It is easy to use, cost-effective, non-invasive and reproducible as well as portable [9]. It has its own limitations, such as inability to detect accurate saturation in conditions such as dyshemoglobinemias (carboxyhemoglobinemia and methemoglobinemia), high arterial oxygen tensions and low perfusion states (low cardiac output, vasoconstriction, and hypothermia) [10].

In this study, patients with locally advanced lesions were treated with chemoradiation. The category of patients with poor SpO2 levels (< 97mmHg) had more residual disease at the end of treatment and hence poorer response to treatment. The patients with better SpO2 levels (≥98 mmHg) had lesser residual disease at the end of treatment comparatively, so probably these tumors were better oxygenated. Radiation causes tissue damage through the formation of free radicals [7]. The free radicals react rapidly with oxygen to ‘fix the damage’. Conversely, under hypoxic conditions, this pattern of damage is reduced, thus resulting in radiation resistance and local recurrence of the tumor [11]. In addition, hypoxia may indirectly promote radioresistance through gene modification, decrease apoptotic potential, thereby reducing theradio-sensitivity of the tumor. The transcriptional regulators of hypoxia, namely HIF-1 and HIF-2 and target genes such as carbonic anhydrase 9 and glucose transporter-1, are reported to have prognostic significance in numerous tumor types [12, 13].

Hypo-oxygenated status has been shown to harbour more aggressive patterns of disease. These tumors present with higher stages at diagnosis, with an increased propensity for metastasis, resistance to therapy and poor survival [11]. In our study, it was observed that patients with poor SpO2 levels had bulkier disease at diagnosis than patients with better SpO2.

In a study by Martins et al., pulse oximetry was found to be a prognostic marker in lung cancer patients [14]. A survival model was developed in these locally advanced lung cancer patients, which included age, performance status, stage and histology. It was found that SpO2>95% was a prognostic marker and an independent predictor of survival.

Anemia is one of the clinically proven prognostic factors. Studies performed on carcinoma cervix have shown that patients with haemoglobin levels less than 10-13g/dl have poorer 5-yr survival [3, 15, 16]. Similarly, in head and neck cancer patients, low haemoglobin levels (<13g/dl for males, <11.5g/dl for females) predicted poorer loco-regional control and overall survival [17]. However, in our study, there was no significant correlation between mean haemoglobin values with a resection in the tumor. Since this is a pilot study, more patients need to be recruited and analysed for the same.

5. LIMITATION OF THE STUDY

This pilot study was performed on a small sample size of 10 patients in a heterogeneous group. Our next endeavour is to include more patients and to categorise them according to site, subsite, histology, tumour markers and correlate SpO2 measurements with the in-vitro assessment of tumour pH [5, 18] and oxygen probes along with studies on gene signatures [12].

CONCLUSION

Patients with lower SpO2 tend to present with bulkier disease at diagnosis and also respond poorly to concurrent chemotherapy. SpO2 readings can be potentially used as a surrogate for tumor oxygenation status in oncology patients. Since it is widely available, easy-to-interpret and non-invasive, it is prudent to further explore its role as a prognostic and predictive indicator in oncology. This pilot study should be done on a larger heterogeneous study population in conjunction with tumor-in-vitro studies and gene-signatures.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The author confirms that since the estimation of SpO2 measurements is a part of routine OPD procedure, it is a non-invasive, 'low-risk' project and does not raise significant ethical issues, only supervisor's (i.e., co-author in this project) approval has been sought.

HUMAN AND ANIMAL RIGHTS

Not Applicable.

CONSENT FOR PUBLICATION

Written informed consent was obtained from all participants.

AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this study are available within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflicts of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Paesmans M. Prognostic and Predictive factors for lung cancer. Breathe (Sheff) 2012; 9(2).
[2] Einoch Amor R, Nakleh MK, Barak O, Haick H. Breath analysis of cancer in the present and the future. Eur Respir Rev 2019; 28(152):190002.
[3] Bush RS. Anemia in radiation therapy, IROHBP, November 1986; 12(1).
[4] Anderson et al. Probe for the measurement of cell surface pH in vivo and ex vivo, PNAS 2016; 113(29): 8177-81.
[5] Horsman MR, Overgaard J. Hypoxia and radiotherapy. J Radiat Res (Tokyo) 2016; 57(51): 90-8.
[6] Thames HD, et al. Accelerated Fractionation vs Hyperfractionation: Rationales for several treatments per day, IROHBP, February 1983; 9(2).
[7] Daimiel I. Insights into hypoxia: non-invasive assessment through imaging modalities and its application in breast cancer. J Breast Cancer 2019; 22(2): 155-71.
[8] Walker PR. Let there be oxygen and T cells. J Clin Invest 2018; 128(11): 4761-3.
[9] Jubb A. Pulse oximetry. Crit Care 2015; 19: 272.
[10] Blaisdell CJ, Goodman S, Clark K, Casella JF, Loughlin GM. Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease. Arch Pediatr Adolesc Med 2000; 154(9): 900-3.
[11] Al Tameemi W, Dale TF, Al-Jumaily RMK, Forryth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol 2019; 7: 4.
[12] Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010; 14(1-2): 18-29.
[13] Yang L, West CML. Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. Br J Radiol 2019; 92(1093):20180036.
[14] Martins SJ, Ho N, Cavamura SO, Harada CM, Yamamoto CA, Takagaki TY. Lung cancer symptoms and pulse oximetry in the prognostic assessment of patients with lung cancer. BMC Cancer 2005; 5: 72.
[15] Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002; 7(6): 492-508.
[16] Mundt AJ, Connell PP, Campbell T, Hwang JH, Rotmensz J, Waggoner S. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 1998; 71(2): 151-8.
[17] Grant DG, Hussain A, Humman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999; 113(9): 829-33.
[18] Boedtkjer, et al. The acidic tumor microenvironment as a driver of cancer, annual review of physiology, annu. Rev Physiol 2020; 82: 21.1-21.24.